A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options

Trial Profile

A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs ISA 101 (Primary) ; Bevacizumab; Carboplatin; Paclitaxel; Peginterferon alfa
  • Indications Cervical cancer; Human papillomavirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CervlSA
  • Sponsors ISA Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results (n=60) assessing association of T cell responses after vaccination with HPV16 long peptides for late stage cervical cancer with prolonged survival, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 04 Apr 2017 Planned End Date changed from 1 Mar 2021 to 1 Sep 2021.
    • 04 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top